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concordant, progressive, or diverse genetic changes. In tumors in
which the differentiation of SCC and BCC is difficult based on
histologic examination only and is of clinical or investigative import-
ance, microdissection of different tumor components with subsequent
genetic analysis may prove to be a useful diagnostic tool in the
future.
Roland Bo¨ni,*† A.O. Vortmeyer,† J. B. Stern,†
G. Burg,* G. Hofbauer,* Z. Zhuang†
*Department of Dermatology, University Hospital, Zu¨rich, Switzerland
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On the Morphogenesis of a Psoriatic Lesion
To the Editor:
In the December issue of the Journal of Investigative Dermatology,
Iizuka et al (1997) made the assumption that the number of total
viable epidermal cells is parallel to that of the proliferative
compartment in the steady state of cell flow.
This is exact for an established lesion of psoriasis where, effectively,
cell loss by desquamation is compensated by an equivalent cell
production by the germinative compartment but cannot explain the
creation of a psoriatic lesion with its typical morphology (Heenen
and Galand, 1984).
What are the minimal kinetic defects needed to generate a
psoriatic-like morphology?
1 The increased size of the germinative compartment corresponds
to a temporary imbalance between the proportion of germinative
cells that repeat the cycle and those that differentiate and migrate
into the differentiating compartment. An acceleration of cell
production (be it by increasing the growth fraction or by reducing
the cell cycle) is insufficient for explaining the growth of the
germinative compartment. When the psoriatic lesion is clinically
stable, this kinetic perturbation has ceased (Heenen et al, 1987).
2 The increased size of the differentiated compartment is determined
by the value of the ratio between the transit time (or residence
time) in the differentiated compartment and the turnover time of
the germinative compartment. Therefore, the morphology of the
psoriatic lesion (increase in absolute size and decrease in relative
size of the differentiated compartment) reflects the fact that the
acceleration of cell transit is more pronounced than that of cell
production in the germinative compartment, and the fact that this
is accompanied by an increase in germinative compartment size.
In conclusion, two perturbations are needed and suffice to account
for the pathogenesis of clinically stable psoriatic lesions: a temporary
disturbance of the steady state of the germinative layers, resulting
in limited growth of this compartment (this has ceased in developed
lesions), and a permanent decrease in the transit time in the
differentiated compartment.
How can the extension of the germinative cell pool be achieved?
Two alternative explanations (not mutually exclusive) can be
proposed. The germinative compartment in human epidermis is
probably composed of a small fraction of stem cells with unlimited
division potential and a greater proportion of transit amplifying cells
already committed to differentiation and with a limited number of
divisions remaining (Potten and Morris, 1988). Increased size of the
1Heenen M, Heenen PH: Extension of the germinative population in
psoriasis. Cell Tissue Kinet 22:169, 1989 (abstr.)
2Laporte M, Galand P, Fokan D, De Graef CH, Heenen M: Apoptosis
in normal skin, psoriasis and healing psoriasis. J Invest Dermatol
106:865, 1996 (abstr.)
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germinative population can be obtained by an increased number of
cell divisions in the amplifying compartment. This hypothesis is
supported by the observation of involucrin in psoriatic lesions, a
terminal differentiation marker, in cells labeled by [3H]thymidine
(Dover and Watt, 1987), and by mathematical simulations.1
Apoptosis is probably an important regulatory mechanism in
epidermal homeostasis. Another possibility is that physiologic apoptosis
in the germinative compartment is temporarily decreased.2 This is
consistent with the observation that psoriatic keratinocytes overexpress
Bcl-xL, a protein that prevents apoptosis (Wrone-Smith et al, 1995).
Michel Heenen
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Reply:
We are grateful for Dr. Heenen’s interest in our paper. As he
correctly points out, we assumed that the total number of viable
epidermal cells paralleled that of the proliferative compartment in a
steady state of cell flow (Iizuka et al, 1997). It should be noted,
however, that we did not intend to explain the creation or
resolution of the psoriatic lesion, which is apparently Dr. Heenen’s
point. Rather, we intended to explain psoriatic architecture in a
steady state of cell flow, which is determined by our assumption.
We would like to point out that this simple assumption is directly
related to in vivo psoriatic morphology and its typically angulated
rete-papilla pattern.
Hajime Iizuka, Hisao Honda,* and Akemi Ishida-Yamamoto
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On the Effect of Estrogen Receptor Agonists and Antagonists
on the Mouse Hair Follicle Cycle
To the Editor:
We were quite surprised to read the Letter to the Editor by Stenn et
al in the Journal of Investigative Dermatology (110:95, 1998), stating that
the estrogen receptor agonist, 17-β-estradiol, and the estrogen receptor
antagonist, ICI 182,780, failed to alter mouse hair cycling. This result
is surprising as we have reported that: (i) the topical application of 17-
β-estradiol arrests hair follicles in telogen, (ii) the topical application
of ICI 182,780 causes telogen follicles to enter anagen, and (iii) the
estrogen receptor is expressed in the nuclei of the dermal papilla cells
of the telogen follicle in CD-1 mice (Oh and Smart, 1996). In their
letter, Stenn et al stated that they ‘‘made a concentrated attempt in
two independent and widely separated laboratories to reproduce the
experiments as described.’’ They further indicated that they ‘‘treated
animals following the Oh/Smart protocol precisely’’ and both of their
studies failed to demonstrate any effect of the agonist or antagonist. It
was most unfortunate that we were not afforded an opportunity to
read and respond to this letter before its publication because it is
obvious that these investigators did not conduct their experiments as
we described. The most profound difference we noted was that they
used doses of 17-β-estradiol and ICI 182,780 that were 5000-fold
lower than the doses we used. Dr. Stenn has confirmed that both his
laboratory and Dr. Paus’s laboratory used a 10 nM dose, which is
5000-fold lower than the correct dose of 10 nmol per 200 µl of
acetone vehicle. This dose is clearly stated in our paper.
In addition, Stenn et al did not use the CD-1 strain of mice that
was used in our studies, but instead used C3H and C57BL/6 mice
because they have ‘‘found that careful hair cycle studies using a
nonpigmented animal such as the CD-1 mouse, are difficult to
interpret.’’ Many high quality, seminal hair follicle cycle studies have
been conducted in nonpigmented mice. While it is of interest to
determine the efficacy of 17-β-estradiol and ICI 182,780 in other
strains of mice, it is regrettable that CD-1 mice were omitted from
their experimental design. The inclusion of CD-1 mice as a positive
control would have allowed these investigators the chance to detect
their dose error, as a 5000-fold lower dose would not be effective in
altering the hair follicle cycle in CD-1 mice, thus indicating that
something was wrong. The use of the correct dose of 17-β-estradiol
and ICI 182,780 would alter the hair follicle cycle in CD-1 mice just
as we reported in our studies. Although we do not know if 17-β-
estradiol and ICI 182,780 will function in C3H and C57BL/6 mice
as they do in CD-1 mice, we do know that other strains of mice such
as SENCAR and TG.AC mice respond to 17-β-estradiol in a manner
similar to CD-1 mice (unpublished results). Experiments to examine
the efficacy of 17-β-estradiol and ICI 182,780 in C57BL/6 and C3H
mice are currently underway in our laboratory.
Addendum We have completed the experiments on the effect of
17-β-estradiol and ICI 182,780 on the hair follicle cycle in C3H and
C57BL/6 mice. Using the experimental conditions described in our
previous publication (Oh and Smart, 1996) we found that in both
C3H and C57BL/6 mice, ICI 182,780 caused telogen follicles to enter
anagen and 17-β-estradiol arrested the hair follicles in telogen. Thus,
if the correct dose (10 nmol per 200 µl acetone vehicle) of estrogen
agonist and antagonist are employed, these agents alter the hair follicle
cycle in C3H and C57BL/6 mice in a manner similar to that previously
described in CD-1 mice.
Robert C. Smart
Molecular and Cellular Toxicology, North Carolina State University
Raleigh, North Carolina
Hye Sun Oh
Cutaneous Biology Research Center, Harvard Medical School
Massachusetts General Hospital, Charlestown, Massachusetts
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Reply:
The experiments we reported in our letter were described as executed,
and the mouse strains investigated were chosen for the reasons stated.
The experiments were planned and conducted completely independent
of one another but, unfortunately, the same mistake was made in both
cases – the concentrations used were not as reported in the original
report. Although we take responsibility for this oversight, we also
recognize that the dosage listing is not entirely conventional to the
field. Before starting the repeat experiments we consulted several
independent researchers outside our respective laboratories; in all cases
the understood dosage was interpreted exactly as we had.
When we repeated the work using the twice weekly protocol and
the concentrations used originally by Oh and Smart (Proc Natl Acad
Sci 93:12525), β-estradiol did indeed inhibit the normal progression
of spontaneous anagen in pigmented mice (C57B16). From additional
and subsequent studies that we have since executed, we have learned
several important features about the role of estrogen receptor-mediated
signaling in murine hair growth control that we did not formerly
appreciate. We would hope to share these data in a future report.
We are indebted to Drs. Oh and Smart for calling our attention to
this interesting phenomenon and regret the confusion our mistake
might have caused.
K. Stenn, R. Paus,* and M. Filippi
Skin Biology Research Centre, Johnson & Johnson, Skillman,
New Jersey, U.S.A.
*Department of Dermatology, Charite Humboldt University, Berlin,
Germany
Note from the Editor: Due to an editorial office error, Drs. Smart
and Oh were not given a chance to reply to the original letter about
their paper by Drs. Stenn, Paus, and Filippi (J Invest Dermatol, 110:95,
1998). We apologize to all the authors for this mistake.
